Literature DB >> 8296850

Antenatal vitamin K therapy of the low-birth-weight infant.

R C Dickson1, T M Stubbs, J Lazarchick.   

Abstract

OBJECTIVE: The purpose of our study was to determine whether maternal vitamin K1 administered antenatally improved global coagulation parameters and the levels of specific vitamin K-dependent proteins in low-birth-weight infants. STUDY
DESIGN: Thirty-three preterm mothers admitted in labor were assigned in a prospective, blinded fashion to receive either intramuscular vitamin K1 (17) or placebo (16). At delivery cord blood samples were tested for prothrombin time, activated partial thromboplastin time, factor II and protein C activity, and antigen levels. Statistical analysis was by Student t test.
RESULTS: No statistically significant differences could be demonstrated with regard to group mean values for global tests (prothrombin time, activated partial thromboplastin time) or specific vitamin K-dependent protein levels (factor II, protein C) in newborns whose mothers received antenatal vitamin K compared with those who did not.
CONCLUSION: These results would suggest that antenatal vitamin K1 therapy to mothers < 32 weeks' gestation has no significant effect on the level of vitamin K-dependent factors in the fetus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8296850     DOI: 10.1016/s0002-9378(94)70389-2

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  3 in total

Review 1.  Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage.

Authors:  Caroline A Crowther; Danielle D Crosby; David J Henderson-Smart
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 2.  Current concepts and controversies in the use of vitamin K.

Authors:  J A Thorp; L Gaston; D R Caspers; M L Pal
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

Review 3.  Prophylactic vitamin K for the prevention of vitamin K deficiency bleeding in preterm neonates.

Authors:  Stephanie Ardell; Martin Offringa; Colleen Ovelman; Roger Soll
Journal:  Cochrane Database Syst Rev       Date:  2018-02-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.